DSL(SH:603233) Zheng Quan Zhi Xing·2025-06-04 11:33Summary of Key Points Core Viewpoint - The major shareholder of Dazhenglin Pharmaceutical Group Co., Ltd., Ke Jinlong, plans to reduce his shareholding by up to 22,776,957 shares, representing a maximum of 2% of the company's total share capital, to adjust asset and financing structure, repay personal debts, and lower stock pledge rates [1][2]. Shareholder Reduction Plan - The reduction period is set from June 27, 2025, to September 26, 2025 [2]. - Ke Jinlong currently holds 229,631,849 shares, accounting for 20.16% of the total share capital [1]. - The reduction will be executed through block trading [1]. - If there are any changes in the company's shares during the reduction period, the number of shares to be reduced will be adjusted accordingly [1]. Shareholder Background - Ke Jinlong is a controlling shareholder and actual controller of the company [1]. - The shareholding structure includes other family members, with Ke Yunfeng holding 242,591,847 shares (21.3%), and Ke Kangbao holding 178,192,742 shares (15.65%) [1]. Previous Commitments - The major shareholders made commitments not to transfer or manage their shares for 36 months post-listing, with specific conditions for future reductions [2][3]. - After the lock-up period, they are allowed to reduce their holdings by no more than 20% of their total shares within specified time frames [2][3].